U.S., April 22 -- ClinicalTrials.gov registry received information related to the study (NCT07542210) titled 'Barriers and Facilitators of Persistence With Adjuvant Osimertinib' on April 14.
Brief Summary: This is a cross-sectional, non-interventional qualitative study using individual interviews to investigate determinants of persistence with 3rd generation EGFR-TKI osimertinib as adjuvant therapy among patients with early-stage NSCLC in China. Approximately 100 participants will be enrolled, comprising around 85 patients and 15 physicians. All participants will be interviewed online or in-person using a COM-B (Capability, Opportunity, Motivation - Behaviour) based guide. Interviews will be conducted in waves, recorded, transcribed, and a...